The new millennium has ushered in a new era in human biology. The elucidation of the human genome sequence, together with those of model organisms, provides us with an unprecedented insight into the makeup of our genetic blueprint. The challenge now is to figure out how all the constituent pieces fit together to form the whole picture, and the consequences of what happens when the process goes awry. One experimental tool that has the potential to provide enormous insights into this complex process is expression profiling using microarrays. The past few years have seen a considerable growth in the availability and use of microarrays. Fuelled in part by the many genome projects currently underway, there has been a large increase in the number of organisms for which microarray reagents are available from both commercial and academic sources. In addition to the increasing number of genomewide probe sets that are available, a significant amount of attention has been focussed on generating more targeted probe sets that focus in on specific pathways or biological processes. Finally, the microarray field is starting to see a shift away from the use of cDNAs or polymerase chain reaction (PCR) products as probes towards the use of 50-70mer oligonucleotide probes with all of the potential advantages that they offer. The aim of this review is to provide an overview of what is currently available in terms of spotted microarray reagents both with respect to pre-made arrays and to probe sets available for arraying.
INTRODUCTION
The advent of DNA microarray technology nearly a decade ago revolutionised the study of gene expression. [1] [2] [3] The ability to grid DNA probes at high density onto solid supports, such as glass slides, meant that, instead of looking at gene expression in a serial or gene-by-gene fashion, it had become possible to measure the expression of thousands of genes in a highly parallel manner. The intervening years have seen considerable developments in microarray technology, both with respect to the reagents available and the methodology employed (for a recent review see Holloway et al. 4 ). Some of these methodological advances will be covered in detail elsewhere in this edition; the aim of this review is to provide an overview of microarray reagents currently available to the researcher, with a particular focus on mammalian and model organisms.
DNA microarrays can be broken down broadly into two types: those where presynthesised probes are deposited onto a support and those where probes are synthesised in situ on the support. Production of the latter type of array is beyond the scope of the academic environment and remains the preserve of commercial manufacturers such as Affymetrix, NimbleGen and Agilent.
3, 5, 6 The Affymetrix GeneChip system will be covered in detail elsewhere in this edition, while this review will focus on the first type of array mentioned, the spotted array. millions of EST sequences for a number of organisms being deposited in GenBank. The complexity of these collections has subsequently been reduced by the assembly of related sequences into clusters by processes such as National Center for Biotechnology Information (NCBI)'s UniGene and The Institute for Genomic Research (TIGR)'s gene indices. 7, 8 By selecting a representative of each cluster, it has been possible to build cDNA clone sets representing the known transcriptomes of many organisms. While these represent a very valuable source of an organism's gene content, for complex organisms -such as man -there remain issues associated with gene coverage that result from the sources of libraries that have been sequenced. A welldocumented example of this relates to genes expressed in the immune system, especially genes expressed in specific cell lineages, at certain time points in development and in response to particular stimuli, which are poorly represented in publicly available databases and hence clone sets. 9 Until very recently, these cDNA clone sets, or, as is currently the case, the PCR products generated from them, have been the primary sources of probes used for spotting onto microarrays (Table 1) . By far the most comprehensive collection of human cDNA clones is that generated by the Integrated Molecular Analysis of Genomes and their Expression (IMAGE) consortium. 10 Both sequence-verified and unverified IMAGE clones are available from a number of distributors worldwide, with the most extensive sets at present being supplied by ResGen, part of the Invitrogen Corporation, and the EST collections provide valuable insight into an organism's transcriptome There are a number of mouse cDNA collections available for the purpose of arraying. The IMAGE consortium has generated a significant number of mouse cDNA clones and sets of sequenceverified clones are available from its distributors. As is the case with human clones, MGC has released a set of fulllength mouse clones, which currently comprises 7,569 clones representing 6,451 known genes. Another clone set that has been extensively used worldwide for microarraying purposes is the National Institute on Aging (NIA) 15K set. 13, 14 This set was derived mainly from early embryonic libraries and has recently been complemented with the release of a second set of 7.4K clones, which are again predominantly derived from early embryonic and stem cell libraries. 15 In total, the combined sets represent an estimated 19,000 unique genes.
A further potential source of clone sets is the Mouse Gene Encyclopaedia Project initiated by RIKEN. 16, 17 This set, which was derived from 246 full-length enriched cDNA libraries, currently comprises 60,770 annotated full-length clones representing 33,409 unique sequences.
Finally, for mouse, Lion Bioscience has released two clone sets, ArrayTAGTM Mouse A and B. The two sets contain cDNA clones derived from nine tissues with each set containing 10,000-sequence verified clones, the majority of which (.70 per cent) correspond to Unigene clusters. These sets have been specifically designed for arraying, such that they have been optimised to give PCR amplification of products of a homogeneous size that are derived from the 39 end of the respective clone.
In comparison to mouse and human, the number of rat microarray reagents is more limited. The primary clone resource has been generated by Dr Bento Soares at the University of Iowa; currently 25,000 sequence-verified clones are available through the IMAGE consortium distributors. Rat reagents are also available from Lion Bioscience, which has developed two 10,000 clone sets that have again been specifically designed for arraying. As with the mouse sets, all clones are sequence verified, with approximately 60 per cent corresponding to rat Unigene clusters.
In addition, centralised gene collections have been established for many other model organisms. An example of this is the Berkeley Drosophila Genome Project, which has developed a cDNA clone set termed the Drosophila Gene Collection. [18] [19] [20] This set currently contains 8,921 sequenced clones derived from a variety of tissues and developmental stages, of which 5,375 contain a fulllength ORF based on alignment with the corresponding genomic sequence.
An alternative strategy used for generating probe sets for arrays has been the design of polymerase chain reaction (PCR) primer sets to amplify entire ORFs from genomic DNA. This approach is particularly suited to organisms that have a higher proportion of intron-less genes. The first example of this approach came from the generation of microarrays for the bakers' yeast Saccharomyces cerevisiae. The completion of the S. cerevisiae genome sequence in 1996 allowed a set of specific PCR primers to be developed for each of the ORFs. 21, 22 These primers were designed to amplify the complete coding region of each ORF from genomic DNA. Currently, more than 6,000 ORF-specific primer pairs are available from ResGen. Other organisms for which ORF-specific primer sets are available include Caenorhabditis elegans, Escherichia coli, Schizosaccharomyces pombe and Bacillus subtilis.
cDNA VERSUS OLIGONUCLEOTIDE PROBES
The availability of large cDNA clone sets clearly enabled the development of the fledgling microarray field. There have also been a number of technical issues associated with their use for the production of arrays, however. These range from problems such as phage contamination of cDNA libraries, the incorrect annotation of individual cDNA clones within sets, through to intellectual property rights issues associated with the use of certain clone sets. 23 Perhaps the biggest challenge facing producers of arrays, however, has come from the logistical headaches involved in minimising the error rate inherent with the high-throughput production and printing of probe sets generated from tens of thousands of bacterial clones. 24 Amongst other things, these logistical issues have prompted a search for alternative types of probe. The most popular alternative that has emerged in recent years is the use of pre-synthesised long (50-70mer) oligonucleotides, which, due to improvements in the reliability of their synthesis, coupled with falling production costs, can now realistically be synthesised in large numbers. In addition, developments in slide surface chemistry (see Holloway et al. 4 for a review of slide manufacturers) have led to improvements in the ability to attach oligonucleotide probes to slides at a sufficient concentration to generate useable signals.
The use of synthetic oligonucleotides in place of PCR products has a number of benefits, although there are still issues that have not yet been comprehensively addressed.
Perhaps the major benefit of using oligonucleotides is the lack of requirement for a physical clone representing the gene of interestprovided of course that sequence information is available. This is particularly beneficial for genes that are expressed in low abundance or in restricted cell types for which cDNA libraries are not readily available. The increasing accessibility of genomic sequences for many organisms will be particularly helpful from this perspective. This lack of requirement for a physical clone brings another benefit, which is flexibility with respect to array design. Probe content can be selected without the need to sift through plates of clones to find genes of interest, which would then need to be rearrayed to generate a format suitable for printing onto slides.
Another potential benefit is that, provided they are designed carefully, oligonucleotide probes should be able to distinguish between the expression patterns of paralogous genes, as they will be less vulnerable to cross-hybridisation effects than PCR products. One potential application for this specificity may be the ability to distinguish been splice variants, a factor that is likely to be of increasing importance given the high degree of alternative splicing being uncovered (reviewed in Modrek and Lee 25 ). Indeed, the ability of 50mer oligonucleotide probes to detect specific splice products on a genomewide scale has recently been demonstrated in a study of mRNA processing in yeast. 26 One issue regarding the use of oligonucleotides as probes is how they perform on arrays, in particular in comparison to PCR probes. Although this has not been widely addressed, in a study that compared 50mer oligonucleotide and PCR probes for eight
genes, Kane and colleagues showed that the oligonucleotides performed with equal sensitivity to the PCR probes. 27 More recently, Wang and co-workers addressed the same issue with a larger set of 65 genes and obtained similar results. In this case, concordant results between probe types were obtained for 60 out of the 65 genes analysed. 28 Oligonucleotide design is going to be central to the issue of performance and a number of software packages have been developed that focus on this. [29] [30] [31] [32] Related to this issue is a drive within the academic array community towards open source oligonucleotide sets. 32 The most comprehensive empirical analysis of aspects of oligonucleotide design on sensitivity and specificity has been carried out by Hughes et al., who found that in situ synthesised 60mers gave good sensitivity and specificity and were able to reliably detect differential transcript levels at one copy per cell. 33 With respect to reducing the costs associated with the use of oligonucleotide arrays, another issue addressed by Hughes and colleagues was the number of oligonucleotides required per transcript to reliably measure changes in abundance. They found that transcript ratios determined using multiple probes were highly consistent, showing on average ,10 per cent variance within a gene. This suggests that a single, carefully chosen oligonucleotide will generally be sufficient.
OLIGONUCLEOTIDE SETS AVAILABLE FOR ARRAYING
The last few years have seen an explosion in the availability of sets of long oligonucleotides for arraying purposes ( Table 2 ). The human, mouse and rat transcriptomes are particularly well covered, with several suppliers making sets for each organism. All suppliers have designed their oligonucleotides with a 39 bias within the template sequence and use a single oligonucleotide per gene. There is little consensus on optimal oligonucleotide length, with lengths ranging from 40-70 nucleotides depending on the supplier. At present, the largest human set is Qiagen's Human Genome Oligo Set, which uses 70mers and covers 21,329 genes. For mouse, the most comprehensive set currently (Table 2) . As mentioned earlier, the use of oligonucleotide probes is starting to enable the development of microarray reagents for a number of organisms, including C. albicans, Plasmodium falciparum, B. subtilis, E. coli K12 and Mycobacterium tuberculosis, for which no large-scale EST sequencing data exist but for which genomic sequences are available (Table 2) .
SOURCES OF MICROARRAYS
For all but the largest scale users of arrays, the most attractive option for obtaining arrays is to get them from an external supplier, whether it is a commercial vendor or an academic microarray core facility. The only real advantage of printing one's own arrays is the flexibility it offers with respect to array content; however, many commercial or academic suppliers now offer a custom array service, albeit at a price. The number of companies selling spotted microarrays is in a continual state of flux. Table 3 lists a number of commercial array suppliers but is by no means exhaustive. For a more extensive list, readers are directed to: http:// ihome.cuhk.edu.hk/$b400559/ array.html. Companies offering spotted cDNA arrays have tended to focus on selling products covering the more extensively studied organisms, namely human, mouse and rat. Companies selling spotted oligonucleotide arrays cover a greater range of organisms. Agilent Technologies, which has recently entered the microarray field, offers cDNA arrays covering human, mouse and rat, but also includes Arabidopsis and S. cerevisiae in its range of catalogue oligonucleotide arrays. MWG Biotech also provides arrays covering a more extensive range of model organisms, as well as a panel of microorganisms (Table 3) .
The production of good quality arrays is not a trivial exercise but is absolutely essential if high quality, reproducible data are to be generated from microarray experiments. As a consequence, academic production is tending to become focused on core facilities as individual groups shy away from printing their own arrays. Table 4 provides details of a number of academic microarray core facilities that supply arrays. A more comprehensive list 
TARGETED ARRAYS
So far, this review has focused on what might be described as broad-coverage arrays rather than more focused or targeted arrays. Targeted arrays contain a much smaller gene content aimed at specific applications or particular biological processes or pathways. In the future, there is likely to be much more demand for targeted arrays as researchers start to use microarrays to address more directed questions concerning specific subsets of genes. The manufacture of targeted arrays is going to require a certain degree of flexibility, making the spotted array format the most suitable for this purpose. In contrast, the production of genome-wide arrays is likely to become more suited to technologies -such as the Affymetrix GeneChip -that will be able to achieve the probe densities required to cover the entire transcriptome of higher organisms.
There is a growing catalogue of companies that produce pre-made targeted arrays (Table 3) . Commercial targeted arrays have a number of emphases. Some focus on genes encoding particular classes of proteins, for example PerkinElmer's MICROMAX range of arrays; others focus on particular biological processes, for example SuperArray's GEArray and GEArray Q series of arrays, while others contain sets of tissue-specific genes. Where no suitable pre-made targeted array exists, the alternative is to generate them in-house from the array of probe sets available. This process will be greatly simplified as the annotation of probe sets improves. Indeed, Compugen already places its oligonucleotide probe sets (Table 2) into functional groups based on its Gene Ontology annotation, allowing researchers to select only the genes involved in the pathways or processes they are particularly interested in for arraying. 34 Targeted arrays generated in-house by academic groups are also becoming more generally available; for example, the authors have developed a spotted oligonucleotidebased, mouse immune response chip that we are making available via the UK MRC HGMP Resource Centre.
CONCLUSION
The past few years have seen an explosion in the availability of spotted microarray reagents, both in terms of the availability of pre-made arrays from commercial and academic sources as well as the number of probe collections available for gridding. Increases in the reliability of the synthesis of long (50-70mer) oligonucleotides, coupled with the falling cost of their synthesis, means that they now represent a viable alternative to the use of PCR products for spotting onto slides. This is reflected in increases in both the numbers of commercially available oligonucleotide-based probe sets and the range of organisms covered by such products. Finally, over the upcoming years it is likely that the microarray field will see a gradual shift away from the use of genome-wide arrays to the use of more focused arrays targeted on particular pathways or biological processes. The flexibility inherent in their production makes medium density spotted arrays the ideal platform for such applications and is likely to ensure that spotted microarrays are around for many years to come.
